Potassium-competitive acid blockers and gastroesophageal reflux disease
Issued Date
2022-07-28
Resource Type
ISSN
10079327
eISSN
22192840
Scopus ID
2-s2.0-85135021857
Pubmed ID
36161043
Journal Title
World Journal of Gastroenterology
Volume
28
Issue
28
Start Page
3608
End Page
3619
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Gastroenterology Vol.28 No.28 (2022) , 3608-3619
Suggested Citation
Leowattana W., Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World Journal of Gastroenterology Vol.28 No.28 (2022) , 3608-3619. 3619. doi:10.3748/wjg.v28.i28.3608 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85706
Title
Potassium-competitive acid blockers and gastroesophageal reflux disease
Author(s)
Other Contributor(s)
Abstract
Proton pump inhibitors (PPIs), the most commonly used antisecretory medications in the management of reflux illness, virtually eliminate elective surgery for ulcer disease, and relegate anti-reflux surgery to patients with gastroesophageal reflux disease (GERD) who are inadequately managed by medical therapy. However, PPI medications still leave some therapeutic demands of GERD unmet. Furthermore, up to 40%-55% of daily PPI users have chronic symptoms, due to PPI refractoriness. Potassium-competitive acid blockers (P-CABs) transcend many of the problems and limits of PPIs, delivering quick, powerful, and extended acid suppression and allowing for treatment of numerous unmet needs. Recently, it has become clear that compromised mucosal integrity plays a role in the etiology of GERD. As a result, esophageal mucosal protection has emerged as a novel and potential treatment approach. An increasing body of research demonstrates that when P-CABs are used as primary drugs or add-on drugs (to regular treatment), they provide a considerable extra benefit, particularly in alleviating symptoms that do not respond to PPI therapy.